Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Financings in Brief: Aastrom Biosciences

This article was originally published in The Gray Sheet

Executive Summary

Aastrom Biosciences: Secondary offering of 2.2 mil. shares of 5-1/2% convertible preferred stock at $5 per share to selected institutional investors on Dec. 2 nets approximately $10 mil. The firm had originally planned an offering of 1.5 mil. common stock shares ("The Gray Sheet" Oct. 20, p. 18). Net proceeds will help fund clinical trials of Aastrom's cell production system, designed for use in large scale ex vivo production of a variety of therapeutic cells ("The Gray Sheet" May 26, I&W-11), as well as R&D of other product candidates, and provide working capital. Cowen & Company was the placement agent for the offering...



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts